An investigation for investors in Onconova Therapeutics Inc over potential securities laws violations by Onconova Therapeutics in connection certain financial statements was announced.
Investors who purchased shares of Onconova Therapeutics Inc (NASDAQ:ONTX), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Onconova Therapeutics Inc (NASDAQ:ONTX) concerning whether a series of statements by Onconova Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On December 4, 2015, post-market, Onconova Therapeutics Inc announced that the FDA had placed a full clinical hold on the investigational new drug application for briciclib, one of Onconova Therapeutics’ secondary clinical-stage product candidates, following a drug product lot testing failure due to visible particulates. Onconova will be required to undertake appropriate remedial actions prior to re-initiating the clinical trial. Onconova Therapeutics Inc said that it previously reported that enrollment in the next cohort of a Phase 1 clinical trial of briciclib was expected to resume upon completion of quality control testing of the drug.
Shares of Onconova Therapeutics Inc (NASDAQ:ONTX) declined to as low as $0.74 per share on January 11, 2016.
Those who purchased shares of Onconova Therapeutics Inc (NASDAQ:ONTX) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego